Enlivex Ltd. (ENLV): Shareholders' Equity
$1.93B
As of 2025-12-31
+224.1%
3-year compound annual growth
n/m
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.93B | n/m | 2026-03-25, Balance as of period end |
| 2024-12-31 | $23.59M | -21.6% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $30.08M | -47.1% | 2026-03-25, Balance as of period end |
| 2022-12-31 | $56.84M | -33.2% | 2025-04-30, Balance as of period end |
| 2021-12-31 | $85.04M | +139.6% | 2024-04-30, Balance as of period end |
| 2020-12-31 | $35.49M | +214.5% | 2023-04-10, Balance as of period end |
| 2019-12-31 | $11.28M | +16.2% | 2022-04-29, Balance as of period end |
| 2018-12-31 | $9.71M | +14.3% | 2021-04-30, Balance as of period end |
| 2017-12-31 | $8.49M | -2.4% | 2020-04-30, Balance as of period end |
| 2016-12-31 | $8.70M | -51.5% | 2020-01-23, Balance as of period end |
| 2015-12-31 | $17.93M | -41.5% | 2018-04-23, Balance as of period end |
| 2014-12-31 | $30.67M | n/m | 2017-02-24, Balance as of period end |
| 2013-12-31 | $175.0K | +133.3% | 2016-03-29, Balance as of period end |
| 2012-12-31 | $75.0K | n/a | 2015-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Enlivex Ltd. (ENLV) | 2025-12-31 | $1.93B | n/m |
| Insmed Inc (INSM) | 2025-12-31 | $738.98M | +158.9% |
| Alkermes plc. (ALKS) | 2025-12-31 | $1.82B | +24.2% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.27B | -7.1% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | -$205.31M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $301.68M | +31.8% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.17B | +69.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
Compare ENLV, INSM, ALKS, OPK side by side · Screen every company in Pharmaceutical Preparations ↗